Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.

Renchi YangJing SunYongqiang ZhaoXuefeng WangDepei WuDespina Tseneklidou-StoeterJunde WuNikki Church

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)

BAY 81-8973 prophylaxis was efficacious and well tolerated in Chinese patients with severe haemophilia A, with ABRs comparable to those in non-Chinese patients receiving prophylaxis.

Keyphrases

early onset
clinical trial
study protocol
phase iii
phase ii
drug induced
water quality
open label
double blind
placebo controlled